VTRS sells JV stake in Humira/Enbrel/Eylea-biosimilars portfolio_to Biocon for $3B plus contingencies… 4Q21 results: https://investor.viatris.com/news-releases/news-release-details/viatris-reports-strong-fourth-quarter-and-full-year-2021 CC slides: https://investor.viatris.com/static-files/6a055dc2-4cd2-4d6c-91c9-c426ec1dcbce Note: VTRS is retaining its participation in the Botox-biosimilar program with RVNC.